Annovis Bio, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA, 19355
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA, 19355
Phone 484-875-3192
Fiscal Year End 1231
EIN 262540421
Financial Overview
FY2024
-$24.59M
Net Income
$17.96M
Total Liabilities
$28.32M
Stockholders' Equity
$10.55M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 8-K Current report of material events | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | December 8, 2025 | View on SEC |
| 4/A Insider transaction amendment | November 25, 2025 | View on SEC |
| 4 Insider stock transaction report | November 25, 2025 | View on SEC |
| 4 Insider stock transaction report | November 21, 2025 | View on SEC |
| 4 Insider stock transaction report | November 18, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| 4 Insider stock transaction report | November 12, 2025 | View on SEC |
| 4 Insider stock transaction report | November 12, 2025 | View on SEC |
Insider Trading
STRONG BUY 1 insiders
12 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.